Please login to the form below

Not currently logged in
Email:
Password:
I have forgotten my password

cancer control

This page shows the latest cancer control news and features for those working in and with pharma, biotech and healthcare.

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

BMS’ Opdivo/Yervoy combination demonstrates OS benefit

Better kidney cancer symptom control reported versus sunitinib was also reported. ... Patients also reported a statistically significant better kidney cancer symptom control with the combination compared to sunitinib when assessed using a valid

Latest news

  • New guide to improve cancer control published in EU New guide to improve cancer control published in EU

    A new guide aiming to save money, time and lives in the fight against cancer has been published by CanCon, the EU co-funded initiative to improve cancer control in Europe. ... Created by a panel of global oncology experts from 126 partner organisations,

  • FDA approves expanded indication for Gilotrif FDA approves expanded indication for Gilotrif

    Boehringer Ingelheim has won US licensing for the expanded use of its EGFR-directed non-small cell lung cancer (NSCLC) drug Gilotrif. ... Overall survival was improved by 19% with the once-daily oral form allowing patients greater control over their

  • Boehringer's Giotrif wins new NSCLC licence in Europe Boehringer's Giotrif wins new NSCLC licence in Europe

    Boehringer Ingelheim's Giotrif (afatinib) has widened its European licence after regulators approved the drug for a type of non-small cell lung cancer (NSCLC). ... Overall survival was improved by 19% and allowed patients a better quality of life as well

  • AZ and BMS earn ASCO plaudits AZ and BMS earn ASCO plaudits

    Both firms tout new combination therapies at the annual cancer congress in Chicago.  . ... The combination of PD-L1 inhibitor MEDI4736 and tremelimumab - a CTLA4 inhibitor - showed clinical activity in patients with advanced non-small cell lung cancer

  • AZ pushes immuno-oncology duo into phase III AZ pushes immuno-oncology duo into phase III

    AstraZeneca (AZ) has reported positive results from a phase Ib clinical trial of MEDI4736 and tremelimumab in lung cancer at ASCO and says it will now take the immuno-oncology combination ... The combination of PD-L1 inhibitor MEDI4736 and tremelimumab -

More from news
Approximately 1 fully matching, plus 23 partially matching documents found.

Latest Intelligence

  • Avoiding data pitfalls in clinical research Avoiding data pitfalls in clinical research

    In a recent pilot study with Roche Pharmaceutical for a rare cancer indication, Medidata’s Synthetic Control Arm (SCA) pulled actual data from past studies to create well-matched control arms. ... The pilot was successful enough to be accepted for

  • Digital disruption Digital disruption

    Combining ‘drag and drop’ computer simulations they’re trying to predict the best way to kill cancer cells with drugs that control their function. ... Next, they draw in the basic signalling pathways that can go wrong in cancer cells.

  • Winning the war against cancer Winning the war against cancer

    At a regional cancer control meeting in Riga last month the Czech Republic, Slovenia and The Netherlands were held up as examples to learn from in areas such as centralised registries, ... work carried out by the likes of the OECD with its Health at a

  • It’s time for pharma companies to become household names It’s time for pharma companies to become household names

    Pharma helps people survive heart attacks, beat cancer, manage depression and control diabetes, but until the companies behind these medicines become a visible part of people's lives, they're never

  • Country report: The healthcare market in South Korea Country report: The healthcare market in South Korea

    The leading cause of death is cancer, followed by cerebrovascular and heart disease. ... The R&D Program for Cancer Control funds research projects by industry, academia and research institutes.

More from intelligence
Approximately 0 fully matching, plus 5 partially matching documents found.

Latest from PMHub

  • World Cancer Day and the role of people-centred care

    play an active role in decisions about their care and respecting their decisions can empower them to regain their sense of control throughout their cancer journey. ... Newsom T. How to cope with loss of control as a cancer patient.

  • Immunotherapy in oncology

    This has led to major progress in disease control and prolonging the survival of cancer patients, but there are still major areas of unmet need. ... Three states of interaction exist in immunoediting;. Elimination, in which the immune response eradicates

  • Enough already. It’s time for pharma companies to become household names

    Pharma helps people survive heart attacks, beat cancer, manage depression and control diabetes, but until the companies behind these medicines become a visible part of people’s lives, they’re never

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Market Access Transformation

Market Access Transformation (MAT), founded by industry veterans Baiju Aurora and Paul Howard, specializes in developing cutting edge technologies that...

Latest intelligence

From lay summaries to patient engagement programmes: how patient-centricity is finally becoming a reality
How pharma is progressing their commitment in patient engagement...
Cuttsy+Cuttsy awarded CPD Platinum by the IPA
Four years after being awarded Gold for their continuous professional development (CPD) Cuttsy+Cuttsy (C+C) have reached another milestone and been awarded Platinum accreditation....
Breaking Bad
Six behaviours separate the good brand teams from the bad...

Quick links

Infographics

Multimedia